Travere Therapeutics (TVTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to -$110.9 million.
- Travere Therapeutics' Enterprise Value fell 20467.74% to -$110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.9 million, marking a year-over-year decrease of 20467.74%. This contributed to the annual value of -$58.5 million for FY2024, which is 61.71% down from last year.
- As of Q3 2025, Travere Therapeutics' Enterprise Value stood at -$110.9 million, which was down 20467.74% from -$75.2 million recorded in Q2 2025.
- Travere Therapeutics' Enterprise Value's 5-year high stood at -$32.3 million during Q2 2024, with a 5-year trough of -$256.6 million in Q1 2022.
- Moreover, its 5-year median value for Enterprise Value was -$83.3 million (2021), whereas its average is -$107.9 million.
- Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 7475.87% in 2024, then plummeted by 20467.74% in 2025.
- Quarter analysis of 5 years shows Travere Therapeutics' Enterprise Value stood at -$165.8 million in 2021, then skyrocketed by 62.78% to -$61.7 million in 2022, then increased by 5.69% to -$58.2 million in 2023, then dropped by 0.62% to -$58.5 million in 2024, then plummeted by 89.51% to -$110.9 million in 2025.
- Its Enterprise Value was -$110.9 million in Q3 2025, compared to -$75.2 million in Q2 2025 and -$61.9 million in Q1 2025.